Objectives: The present study was performed to use chemerin as early predictor of metabolic syndrome in CKD patients to rule out risk of CVD.Methods: Our study included sixty adult CKD patients stage 3, 4 and 5.The chronic kidney disease at group (I) were 8 females and 22 males with mean of age 53+12years. The patients of group (II) were 10 females and 20 males with mean of age 48+14.8years. All our patients were subjected to history taking, clinical examination and laboratory investigation including serum creatinine, chemerin and Body composition assessed by measuring total fat mass and truncal fat mass by dual energy x-ray absorptiometry using the DEXA device, with twenty healthy adults of matching age and sex served as a control group.Results: This study proved that risk of IHD increased with regression of kidney function. Mean chemerin level was higher in CKD group than ESRD and control group. Mean chemerin level has a positive correlation with HOMA index, serum creatinine level in group I and II and negative correlation with eGFR. Chemerin has sensitivity 72%, specificity 65% and accuracy 60% to detect metabolic syndrome in CKD and ESRD patients. Conclusion: Our results support the hypothesis that chemerin may be an insulin resistance adipokine and clarify the role of chemerin in uremic dysmetabolism.